{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:38:55Z","timestamp":1778038735603,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004776","name":"Chulalongkorn University MDCU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["0527\/66"],"award-info":[{"award-number":["0527\/66"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jctube.2026.100590","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T16:06:34Z","timestamp":1771085194000},"page":"100590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Prevalence and risk factors associated with rifampicin-induced cholestasis jaundice among tuberculosis patients in high-incidence setting: A retrospective cohort study"],"prefix":"10.1016","volume":"43","author":[{"given":"Manunchaya","family":"Sintusuwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyapan","family":"Prueksapanich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-7440","authenticated-orcid":false,"given":"Gompol","family":"Suwanpimolkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jctube.2026.100590_b0005","unstructured":"World Health Organization. Global tuberculosis report 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240037021; [accessed April 6, 2025]."},{"key":"10.1016\/j.jctube.2026.100590_b0010","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention MMWR. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/rr\/pdfs\/rr6901a1-H.pdf; [accessed April 6, 2025].","DOI":"10.15585\/mmwr.rr6901a1"},{"key":"10.1016\/j.jctube.2026.100590_b0015","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jctube.2026.100590_b0020","first-page":"699","article-title":"Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore","volume":"6","author":"Teleman","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jctube.2026.100590_b0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0041-3879(76)90045-3","article-title":"isoniazid, pyrazinamide and rifampicin in Hong Kong","volume":"57","author":"Adverse reactions to short-course regimens containing streptomycin","year":"1976","journal-title":"Tubercle"},{"key":"10.1016\/j.jctube.2026.100590_b0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5694\/j.1326-5377.1971.tb50435.x","article-title":"The Australian rifampicin trial","volume":"2","author":"Proust","year":"1971","journal-title":"Med J Aust"},{"key":"10.1016\/j.jctube.2026.100590_b0035","unstructured":"World Health Organization. Definitions and reporting framework for tuberculosis \u2013 2013 revision, updated December 2014 and January 2020. https:\/\/www.who.int\/publications\/i\/item\/9789241505345; [accessed April 6, 2025]."},{"key":"10.1016\/j.jctube.2026.100590_b0040","unstructured":"National Library of Medicine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/; 2012 [accessed April 6, 2025]."},{"key":"10.1016\/j.jctube.2026.100590_b0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/MOG.0000000000000176","article-title":"Aging and liver disease","volume":"31","author":"Kim","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jctube.2026.100590_b0050","first-page":"146","article-title":"Extra-pulmonary TB, low BMI, and hypoalbuminemia as risk factors for TB-DILI","volume":"14","author":"Kamei","year":"2013","journal-title":"Drug Discov Ther"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579426000124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579426000124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:05:09Z","timestamp":1777601109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579426000124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"alternative-id":["S2405579426000124"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100590","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and risk factors associated with rifampicin-induced cholestasis jaundice among tuberculosis patients in high-incidence setting: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100590"}}